Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Omeprazole

Preparation Calculator

USE IF: Documented GERD/PUD, selected NSAID ulcer prevention, H. pylori regimens, IV upper GI bleed or ICU stress-ulcer pathways per protocol β€” with duration limits, deprescribing plan, and alarm-feature workup when symptoms persist.

AVOID IF: Indefinite continuation without indication; ignoring clopidogrel interaction in high-risk CV patients when alternatives exist; alarm symptoms without evaluation; abrupt stop after chronic use without rebound mitigation plan.

Omeprazole

Proton pump inhibitor (PPI)

AdultPediatricGIPPIERWardICUClinic

Indication

GERD / PUD β€’ NSAID gastroprotection (selected) β€’ H. pylori β€’ IV GI bleed (protocol) β€’ Stress ulcer prophylaxis (ICU only) β€’ Short dyspepsia trial

At a glance

INDICATIONS (CORE USE)

- GERD - Peptic ulcer disease (PUD) - NSAID-related ulcer prevention (selected patients) - H. pylori eradication (combination therapy)

ADULT DOSE (STANDARD)

GERD / dyspepsia: 20 mg PO daily PUD: 20–40 mg PO daily H. pylori: component of combination regimen (per protocol) IV GI bleed: bolus Β± infusion per institutional guideline

MAX DOSE

Indication-specific β€” avoid a single universal β€œmax” without indication and monitoring context

Route

PO / IV

PEDIATRIC DOSE

Weight-based; protocol-guided

Do not miss

Must-not-miss safety points

Major warning

- Overuse / prolonged use without indication is common and harmful - Long-term use β†’ hypomagnesemia, B12 deficiency, fracture risk, infections (C. difficile) - Drug interaction with clopidogrel (CYP2C19 inhibition β†’ ↓ antiplatelet effect) - Masking serious pathology (e.g., malignancy) if used without evaluation - Rebound acid hypersecretion after abrupt discontinuation

Indications

Primary

  • GERD
  • Peptic ulcer disease (PUD)
  • NSAID-related ulcer prevention (selected patients)
  • H. pylori eradication regimens (combination therapy)

Secondary

  • Upper GI bleeding (IV protocol context)
  • Stress ulcer prophylaxis (ICU / high-risk patients only)

Other

  • Dyspepsia (short-term trial only; reassess)

Dosing

STANDARD (ADULT PO)

GERD / dyspepsia: 20 mg PO daily PUD: 20–40 mg PO daily H. pylori: part of combination regimen (per protocol)

ADULT DOSE

IV GI bleed: protocol-based bolus + infusion or intermittent dosing per guideline Use lowest effective dose Time-limited therapy unless clear ongoing indication Reassess need regularly

PEDIATRIC DOSE

Weight-based; protocol-guided

MAX DOSE

Indication-specific β€” titrate to symptom/endoscopic/bleed context; avoid reflex chronic escalation

Practical Note

DURATION / DEPRESCRIBING (critical) - Uncomplicated GERD / dyspepsia: trial 2–8 weeks β†’ reassess indication and alarm features - Long-term only with clear indication (e.g., severe GERD, Barrett’s, high-risk NSAID co-therapy per protocol) Deprescribing: - Step down dose or switch to PRN when appropriate - Consider gradual taper to reduce rebound acid hypersecretion after chronic use - Common error = indefinite continuation without indication

Warnings

Clinical warnings

  • C. difficile infection risk
  • Pneumonia (context: early hospitalization / aspiration risk populations)
  • Hypomagnesemia (long-term)
  • B12 deficiency (chronic use)
  • Fracture risk with prolonged use
  • Masking of serious disease β€” persistent symptoms need evaluation (not dose stacking)

Contraindications

  • Known hypersensitivity

Drug interactions

  • Clopidogrel β†’ reduced active metabolite formation (CYP2C19); clinical significance context-dependent β€” highest concern in high-risk CV patients when alternatives feasible
  • Warfarin β†’ possible INR shifts β€” monitor when starting/stopping/changing PPI
  • Drugs needing acidic gastric pH (e.g., selected antifungals, iron, ketoconazole, atazanavir) β†’ reduced absorption / efficacy
  • CYP2C19 substrates with narrow index (e.g., citalopram, phenytoin) β†’ monitor clinically when coprescribed

Special populations

Pediatrics

Weight-based; protocol-guided

Pregnancy

Pregnancy: use lowest effective dose for shortest duration when benefit outweighs risk; follow current labeling and specialist input.

Lactation

excreted in milk; usually compatible at typical doses β€” confirm local guidance.

Renal impairment

No major dose adjustment β€” still reassess indication duration and electrolytes if prolonged use.

Hepatic impairment

Severe hepatic impairment may warrant dose consideration β€” follow labeling / local protocol.

Elderly

Higher long-term adverse-effect burden β€” reassess indication and dose regularly; watch falls/fracture context.

Administration

- Give before meals (preferably morning) - Do not crush certain formulations β€” follow product-specific guidance - IV reserved for appropriate inpatient indications (bleed / inability to take PO per protocol)

Monitoring

  • Monitor: - Symptom response - Indication validity (ongoing need) - Electrolytes (Mg if prolonged use) - Signs of GI bleeding if relevant
  • Recheck: - 2–8 weeks after initiation for most outpatient indications - Regular review for long-term users - Reassess sooner if alarm symptoms or new instability
  • Hold / reassess: - No clear indication for continuation - New concerning GI symptoms (weight loss, anemia, bleeding) - Significant electrolyte abnormalities

Overdose / toxicity

Clinical Picture

Generally mild acute overdose (nausea, dizziness, headache) High-dose chronic exposure β†’ electrolyte / metabolic issues

Immediate Actions

Supportive care Hold unnecessary PPI if ingestion is iatrogenic stack

Antidote

None β€” supportive care

Decontamination

Massive acute ingestion: supportive care; poison center if unstable or co-ingestants.

Escalation

Severe electrolyte derangement or refractory symptoms β†’ escalate per protocol.

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield

  • Most patients do NOT need long-term PPI
  • Reassess every prescription renewal

Clinical

  • Clopidogrel interaction matters most in high-risk CV patients
  • If symptoms persist despite PPI β†’ reassess diagnosis, not only increase dose

Safety

  • Common mistake = indefinite continuation without indication

Pharmacy Tool

Preparation Calculator

Omeprazole 2 mg/mL oral suspension

suspension Β· oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

- Short plasma half-life; prolonged acid suppression - Hepatic metabolism (CYP system, prominently CYP2C19)

Mechanism of action

- Irreversible proton pump inhibition in gastric parietal cells

Common brand names

Saudi Arabia

Losec, Gastroloc, Omez

Global

Prilosec, (placeholder β€” verify local formulation)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

Global data (no country-specific data available)

  • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
  • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • ACG / dyspepsia and GERD management guidance
  • Maastricht / H. pylori consensus (where applicable)
  • ICU stress ulcer prophylaxis institutional protocols
  • FDA / SFDA product labeling and clopidogrel interaction references